Astellas Pharma, Inc. et al. v. Ascent Pharmaceuticals, Inc.
Infringement action filed 4 May 2023 in the United States District Court for the Eastern District of New York and closed 5 Jul 2023, with US10842780B2 asserted. Recorded basis of termination: voluntary dismissal.
Case record
- Patent involved
- US10842780B2
- Application no.
- US15/432854
- Case no.
- 2:23-cv-03372
- Verdict cause
- Infringement action
- Court
- E.D.N.Y.
- Court level
- District Court
- Case region
- New York
- Chief judge
- None recorded
- Trial level
- First instance
- Filed – Closed
- 4 May 2023 – 5 Jul 2023
- Duration
- 62 days
- Basis of termination
- Voluntary dismissal
- Products & marks
- Pharmaceutical composition for modified release
- Validity challenges
- None recorded
Check this patent against your own product
Prior art, claim scope, infringement exposure and design-around routes. Every answer cites the records behind it.
Get an FTO claim chart- 01Ranked prior artEvery hit source-linked
- 02Claim-level comparisonAgainst your own product
- 03Legal statusAcross 174 jurisdictions
Pharmaceutical composition for modified release
A pharmaceutical composition for modified release, comprising (1) (R)-2-(2-aminothiazol-4-yl)-4′-[2-[(2-hydroxy-2-phenylethyl)amino]ethyl]acetic acid anilide, or a pharmaceutically acceptable salt thereof, (2) at least one additive which ensures penetration of water into the pharmaceutical composition and which has a solubility such that the volume of water required for dissolving 1 g of the additive is 10 mL or less, and (3) a hydrogel-forming polymer having an average molecular weight of approximately 100,000 or more, or a viscosity of 12 mPa·s or more at a 5% aqueous solution at 25° C. is disclosed.
- Legal status
- Active
- Granted
- 24 Nov 2020
- Earliest priority
- 30 Sep 2008
- Est. expiry
- 28 Mar 2030
- Validity challenges
- None recorded
- Licences recorded
- None recorded
- Inventors
- TAKAISHI, YUUKI · TAKAHASHI, YUTAKA · NISHIZATO, TAKASHI · MURAYAMA, DAISUKE · MURAYAMA, EMIKO · NAKAMURA, SOICHIRO · SAKO, KAZUHIRO
- Classification
- A61K31/426A61K9/20A61K9/28
- Prosecution counsel
- Venable LLP
- Examiner
- LUNDGREN, JEFFREY S
Parties of record
Astellas Pharma, Inc.
- Core tech
- A61K31/426A61K9/20A61K9/28
- Counsel
- Jason Albert Leonard · Simon Roberts
- Firm
- McDermott Will & Emery LLP
- Also named
- Astellas Pharma Global Development, Inc. · Astellas Ireland Co., Ltd.
Ascent Pharmaceuticals, Inc.
- Core tech
- Not recorded
- Counsel
- Not recorded
- Firm
- Not recorded
Counsel of record
| Attorney | For | Role |
|---|---|---|
| Jason Albert Leonard | Astellas Pharma, Inc. | Plaintiff |
| Simon Roberts | Astellas Pharma, Inc. | Plaintiff |
Basis of termination
From the record · verbatim“Pursuant to Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure, Plaintiffs Astellas Pharma Inc., Astellas Ireland Co., Ltd., and Astellas Pharma Global Development, Inc. hereby give notice that their complaint against defendant Ascent Pharmaceuticals, Inc. in the above captioned action is voluntarily dismissed without prejudice.”
Case 2:23-cv-03372 · E.D.N.Y. · closed 5 July 2023
Related cases
Three questions this record usually leads to. Each one runs against the full litigation and patent corpus, and cites what it finds.
Frequently asked questions
What is case 2:23-cv-03372?
2:23-cv-03372 is a patent infringement action brought by Astellas Pharma, Inc. against Ascent Pharmaceuticals, Inc., filed on 4 May 2023 in the United States District Court for the Eastern District of New York. The case closed on 5 July 2023.
Which patent was asserted in 2:23-cv-03372?
US10842780B2 (“Pharmaceutical composition for modified release”), assigned to ASTELLAS PHARMA INC., currently active. The record also lists Pharmaceutical composition for modified release.
How was case 2:23-cv-03372 terminated?
The recorded basis of termination is voluntary dismissal. The termination text reads: “Pursuant to Rule 41(a)(1)(A)(i) of the Federal Rules of Civil Procedure, Plaintiffs Astellas Pharma Inc., Astellas Ireland Co., Ltd., and Astellas Pharma Global Development, Inc. hereby give notice that their complaint against defendant Ascent Pharmaceuticals, Inc. in the above captioned action is voluntarily dismissed without prejudice.”
What does dismissal without prejudice mean?
A dismissal without prejudice ends this action but leaves the claims alive — the plaintiff may file them again later, subject to the limitation period.
How long did case 2:23-cv-03372 take?
62 calendar days, from filing on 4 May 2023 to closure on 5 July 2023.
Who were the attorneys and the judge in 2:23-cv-03372?
Jason Albert Leonard and Simon Roberts are recorded as counsel for plaintiff Astellas Pharma.
Disclaimer. This page reproduces publicly available court docket data for case 2:23-cv-03372 and is provided for general information and reference only. It is not legal advice and must not be relied upon as such.
Docket data has limits. Records are drawn from a snapshot and may lag the live docket. Sealed filings, amended complaints, counterclaims and post-closure motions may not be reflected. Party names, attorney names and firm affiliations are reproduced as recorded and may contain omissions. Where a field is absent from the record, this page marks it as not recorded rather than inferring a value.
No characterisation of the parties or the outcome. This page reports what the record contains. Nothing here should be read as an assertion that any party infringed, that any patent is valid or invalid, that any settlement occurred, or that any party prevailed.
No FTO or validity opinion. Nothing on this page constitutes a freedom-to-operate, novelty, validity or infringement opinion. Any decision touching a live patent dispute should be verified independently and reviewed with qualified patent counsel.